Halladay Benjamin's Insider Trades & SAST Disclosures
Halladay Benjamin's most recent trade in Esperion Therapeutics Inc. was a trade of 3,535 Common Stock done at an average price of $1.5 . Disclosure was reported to the exchange on March 18, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Halladay Benjamin.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Esperion Therapeutics Inc. | Benjamin Halladay | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.48 per share. | 18 Mar 2025 | 3,535 | 481,710 (1%) | 0% | 1.5 | 5,242 | Common Stock |
| Esperion Therapeutics Inc. | Benjamin Halladay | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 238,000 | 485,245 (1%) | 0% | 0 | Common Stock | |
| Esperion Therapeutics Inc. | Benjamin Halladay | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 213,000 | 213,000 | - | - | Stock Option (right to buy) | |
| Esperion Therapeutics Inc. | Benjamin Halladay | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.82 per share. | 19 Feb 2025 | 11 | 240,671 (0%) | 0% | 1.8 | 20 | Common Stock |
| Esperion Therapeutics Inc. | Benjamin Halladay | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.22 per share. | 17 Jan 2025 | 9 | 240,682 (0%) | 0% | 2.2 | 20 | Common Stock |
| Esperion Therapeutics Inc. | Halladay Benjamin | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.42 per share. | 17 Dec 2024 | 3,245 | 240,691 (0%) | 0% | 2.4 | 7,866 | Common Stock |
| Esperion Therapeutics Inc. | Benjamin Halladay | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Esperion Therapeutics Inc. | Benjamin Halladay | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 170,000 | 243,936 (0%) | 0% | 0 | Common Stock | |
| Esperion Therapeutics Inc. | Benjamin Halladay | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 39,000 | 39,000 | - | - | Stock Option (right to buy) | |
| Esperion Therapeutics Inc. | Benjamin Halladay | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 9,200 | 73,936 (0%) | 0% | 0 | Common Stock | |
| Esperion Therapeutics Inc. | Benjamin Halladay | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2022 | 66,000 | 66,000 | - | - | Stock Option (right to buy) | |
| Esperion Therapeutics Inc. | Benjamin Halladay | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2022 | 44,000 | 63,771 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges